Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

A Phase 3 study of Cabozantinib + Atezolizumab in Subjects with Metastatic Castration-Resistant Pros

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

Disease Types: Prostate

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT04446117?term=A+Phase+3%2C+Randomized%2C+Open-Label%2C+Controlled+Study+of+Cabozantinib+%28XL184%29+in+Combination+with+Atezolizumab+vs+Second+Novel+Hormonal+Therapy+%28NHT%29+in+Subjects+with+Metastatic+Castration-Resistant+Prostate+Cancer&draw=1&rank=1